Dao Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| DAO Gene |
|---|
| Gene Symbol | DAO |
| Full Name | D-Amino Acid Oxidase |
| Chromosomal Location | 12q24.11 |
| NCBI Gene ID | 1680 |
| OMIM | 124050 |
| Ensembl ID | ENSG00000110888 |
| UniProt | P14920 |
| Associated Diseases | Amyotrophic Lateral Sclerosis, Schizophrenia |
DAO (D-Amino Acid Oxidase) encodes an enzyme that catalyzes the oxidative deamination of D-amino acids. This flavin adenine dinucleotide (FAD)-dependent oxidase plays a crucial role in the metabolism of D-serine, a key NMDA receptor co-agonist in the brain. DAO activity is implicated in amyotrophic lateral sclerosis (ALS) and schizophrenia, making it an interesting therapeutic target for neurodegenerative and psychiatric disorders[1].
The DAO gene contains:
- Exons: 13 coding exons
- Promoter: Contains regulatory elements for brain expression
- Alternative Splicing: Multiple transcript variants
DAO participates in amino acid metabolism:
- D-Serine Metabolism: Oxidizes D-serine to produce hydroxylaminopyruvate
- NMDA Receptor Regulation: Controls D-serine levels, an NMDAR co-agonist
- Neurotransmission: Modulates glutamatergic signaling
- Amino Acid Homeostasis: Degrades D-amino acids from diet and metabolism
DAO functions through:
- FAD-dependent Oxidation: Uses FAD as cofactor
- D-Amino Acid Binding: Substrate-specific binding pocket
- Hydrogen Peroxide Production: Generates H2O2 as byproduct
- Peroxisomal Localization: Primarily localized to peroxisomes
DAO is expressed in:
DAO is implicated in ALS pathogenesis:
- Increased Activity: Elevated DAO in ALS patient tissue
- D-Serine Depletion: Reduced D-serine affects NMDAR signaling
- Excitotoxicity: Altered glutamate signaling
- Therapeutic Target: DAO inhibitors in development[2]
DAO is a risk gene for schizophrenia:
- Genetic Associations: DAO variants linked to schizophrenia risk
- D-Serine Hypothesis: Altered D-serine metabolism
- NMDA Receptor Dysfunction: Contributes to cognitive deficits
- Alzheimer's Disease: Altered D-serine metabolism
- Epilepsy: DAO activity affects seizure threshold
- Huntington's Disease: May modulate excitotoxicity
Strategies targeting DAO:
- DAO Inhibitors: Reduce excessive DAO activity
- D-Serine Supplementation: Bypass DAO-mediated depletion
- FAD Modulators: Modulate DAO cofactor availability
- Gene Therapy: AAV-mediated DAO modulation
Key research priorities:
- Understanding DAO regulation in different cell types
- Developing selective DAO inhibitors
- Biomarkers for D-serine pathway activity
- Links between DAO and other neurodegenerative processes
- Burnet PW, et al. (2011). D-amino acid oxidase in schizophrenia. Schizophr Bull. PMID:21324941
- Sasabe J, et al. (2007). D-serine and D-amino acid oxidase in ALS. Ann Neurol. PMID:17415985
- Van Vliet T, et al. (2014). DAO and NMDA receptor signaling. Neuropharmacology. PMID:24389459
The study of Dao Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Burnet PW, et al. (2011). D-amino acid oxidase in schizophrenia. Schizophr Bull. PMID:21324941
- Sasabe J, et al. (2007). D-serine and D-amino acid oxidase in ALS. Ann Neurol. PMID:17415985
- Van Vliet T, et al. (2014). DAO and NMDA receptor signaling. Neuropharmacology. PMID:24389459
- Morikawa A, et al. (2001). D-serine metabolism in brain. J Neurochem. PMID:11267608
- Fukushima T, et al. (2004). D-amino acid oxidase functions. Biochim Biophys Acta. PMID:14741744